Nurix Therapeutics (NASDAQ:NRIX) just reported results for the first quarter of 2024.
- Nurix Therapeutics reported earnings per share of -76 cents. This was above the analyst estimate for EPS of -80 cents.
- The company reported revenue of $16.59 million.
- This was 0.33% worse than the analyst estimate for revenue of $16.64 million.